SOX10 and neoplasm: Molecularly, SOX10 upregulation closely correlates with NRAS oncogene expression, and importantly, even partial reduction of SOX10 (haploinsufficiency) significantly impedes tumor cell proliferation,48, 49 suggesting a potential therapeutic window where partial inhibition might achieve clinical benefit without complete disruption of normal melanocyte function.